MBD2 is a methyl-CpG binding domain protein that serves as a key epigenetic regulator of transcriptional silencing. MBD2 binds methylated CpG dinucleotides in gene promoters, including hemimethylated DNA 123. It recruits histone deacetylases and DNA methyltransferases to chr18, functioning as a core component of the NuRD (nucleosome remodeling and deacetylase) complex 425. Through its intrinsically disordered region, MBD2 interacts with the histone deacetylase core of NuRD to establish repressive chr18 states and silence tumor suppressor genes 6. MBD2 also acts as a scaffold protein targeting GATAD2A/B to chr18 and forms redox-sensitive nuclear condensates that stabilize heterochromatin 78. Clinically, MBD2 overexpression promotes chemoresistance in cholangiocarcinoma through WDR5-mediated ABCB1 activation 9. In pulmonary fibrosis, MBD2 in macrophages represses SHIP expression, enhancing M2 polarization and fibrosis; MBD2 knockdown protects against bleomycin-induced injury 1011. MBD2 is essential for colorectal tumorigenesis and represents a therapeutic target 12. Conversely, MBD2 downregulation is necessary for normal erythropoiesis and can reactivate silenced fetal globin genes in β-hemoglobinopathies 1314. These findings establish MBD2 as a contextual regulator controlling both pathological and physiological gene silencing programs.